Welcome to LookChem.com Sign In|Join Free
  • or
2-Butanone, 4-methoxy-3,3-dimethyl- (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

80783-13-7

Post Buying Request

80783-13-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

80783-13-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 80783-13-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,0,7,8 and 3 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 80783-13:
(7*8)+(6*0)+(5*7)+(4*8)+(3*3)+(2*1)+(1*3)=137
137 % 10 = 7
So 80783-13-7 is a valid CAS Registry Number.

80783-13-7Downstream Products

80783-13-7Relevant academic research and scientific papers

A tris-pyrazolylborate ligand with hemilabile O-donor groups. Examples of η3, η5, η6 and bridging modes of bonding to Li+, Na+, K+, Tl+ and Ca2+ ions

Chisholm, Malcolm H.,Gallucci, Judith C.,Yaman, Guelsah

, p. 1872 - 1874 (2006)

A tris-pyrazolylborate ligand bearing ether appendages is shown to be a potential hemilabile ligand based on NMR studies and structural characterization of its η3, η5, η6, and μ-binding modes in coordination with Li+, Na+, K +, Tl+, and Ca2+ ions. The Royal Society of Chemistry 2006.

COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN INTERFERON

-

, (2017/07/27)

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBsAg inhibitor and an interferon for use in the treatment or prophylaxis of chronic Hepatitis B virus infections.

COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN HBV CAPSID ASSEMBLY INHIBITOR

-

, (2017/07/14)

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBs Ag inhibitor and an HBV capsid assembly inhibitor for use in the treatment or prophylaxis of chronic hepatitis B infected patients.

NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

-

Page/Page column 34; 35, (2016/06/01)

The invention provides novel compounds having the general formula (I) wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

4-Substituted 3,3-dimethyl-butan-2-ones, processes for their preparation and their use as intermediate products

-

, (2008/06/13)

4-substituted 3,3-dimethyl-butan-2-ones of the formula STR1 in which R represents cyano or the grouping --X--R1, wherein R1 represents n-alkyl with 1 to 4 carbon atoms, isopropyl, isobutyl, sec.-butyl, alkenyl with 3 to 4 carbon atom

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 80783-13-7